{"id":847732,"date":"2025-05-06T16:48:06","date_gmt":"2025-05-06T20:48:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\/"},"modified":"2025-05-06T16:48:06","modified_gmt":"2025-05-06T20:48:06","slug":"sangamo-therapeutics-announces-first-quarter-2025-earnings-call","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\/","title":{"rendered":"Sangamo Therapeutics Announces First Quarter 2025 Earnings Call"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Sangamo Therapeutics Announces First Quarter 2025 Earnings Call<\/b><\/p>\n<p>RICHMOND, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nSangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company has scheduled the release of its first quarter 2025 financial results after the markets close on Monday, May 12, 2025.\n<\/p>\n<p>\nThe company will hold a conference call at 4:30 p.m. Eastern on Monday, May 12, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates.\n<\/p>\n<p>\nParticipants should register for, and access, the call using <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fregister-conf.media-server.com%2Fregister%2FBI3ca9a6763be84baaa667afd60ae6be26&amp;esheet=54249533&amp;newsitemid=20250506737112&amp;lan=en-US&amp;anchor=this+link&amp;index=1&amp;md5=ecc2927c3f3b8bc9a5747bbdbdf55534\">this link<\/a>. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.sangamo.com%2Fevents-and-presentations&amp;esheet=54249533&amp;newsitemid=20250506737112&amp;lan=en-US&amp;anchor=Events&amp;index=2&amp;md5=e24bb864d5f3a79b5b6531119ceb24eb\">Events<\/a>.\n<\/p>\n<p>\nA replay will be available following the conference call, accessible under <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.sangamo.com%2Fevents-and-presentations&amp;esheet=54249533&amp;newsitemid=20250506737112&amp;lan=en-US&amp;anchor=Events&amp;index=3&amp;md5=db22ccfe642778ffca411e8dc3ef5dfe\">Events<\/a>.\n<\/p>\n<p><b>About Sangamo Therapeutics<\/b><\/p>\n<p>\nSangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo\u2019s pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sangamo.com&amp;esheet=54249533&amp;newsitemid=20250506737112&amp;lan=en-US&amp;anchor=www.sangamo.com&amp;index=4&amp;md5=7a1e99e6ab69c1b952012ec30cfed6c6\">www.sangamo.com<\/a> and connect with us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsangamo-therapeutics&amp;esheet=54249533&amp;newsitemid=20250506737112&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=3e2a3c478aee0b9c18a6837ef4b816d5\">LinkedIn<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FSangamoTx&amp;esheet=54249533&amp;newsitemid=20250506737112&amp;lan=en-US&amp;anchor=X&amp;index=6&amp;md5=1b1351b9338819503cb242aaee001fb3\">X<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250506737112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250506737112\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250506737112\/en\/<\/a><\/span><\/p>\n<p><b>Investor Relations<br \/>\n<\/b><br \/>Louise Wilkie<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@sangamo.com\">ir@sangamo.com<\/a><\/p>\n<p><b>Media Inquiries<br \/>\n<\/b><br \/>Melinda Hutcheon<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:media@sangamo.com\">media@sangamo.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Neurology Biotechnology Pharmaceutical General Health Health Health Technology Genetics Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250506737112\/en\/736004\/3\/Sangamo_logoTM.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Sangamo Therapeutics Announces First Quarter 2025 Earnings Call RICHMOND, Calif.&#8211;(BUSINESS WIRE)&#8211; Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company has scheduled the release of its first quarter 2025 financial results after the markets close on Monday, May 12, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Monday, May 12, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Sangamo Therapeutics Announces First Quarter 2025 Earnings Call&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-847732","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sangamo Therapeutics Announces First Quarter 2025 Earnings Call - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sangamo Therapeutics Announces First Quarter 2025 Earnings Call - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Sangamo Therapeutics Announces First Quarter 2025 Earnings Call RICHMOND, Calif.&#8211;(BUSINESS WIRE)&#8211; Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company has scheduled the release of its first quarter 2025 financial results after the markets close on Monday, May 12, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Monday, May 12, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into &hellip; Continue reading &quot;Sangamo Therapeutics Announces First Quarter 2025 Earnings Call&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-06T20:48:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250506737112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sangamo Therapeutics Announces First Quarter 2025 Earnings Call\",\"datePublished\":\"2025-05-06T20:48:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\\\/\"},\"wordCount\":336,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250506737112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\\\/\",\"name\":\"Sangamo Therapeutics Announces First Quarter 2025 Earnings Call - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250506737112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-05-06T20:48:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250506737112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250506737112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sangamo Therapeutics Announces First Quarter 2025 Earnings Call\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sangamo Therapeutics Announces First Quarter 2025 Earnings Call - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\/","og_locale":"en_US","og_type":"article","og_title":"Sangamo Therapeutics Announces First Quarter 2025 Earnings Call - Market Newsdesk","og_description":"Sangamo Therapeutics Announces First Quarter 2025 Earnings Call RICHMOND, Calif.&#8211;(BUSINESS WIRE)&#8211; Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company has scheduled the release of its first quarter 2025 financial results after the markets close on Monday, May 12, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Monday, May 12, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into &hellip; Continue reading \"Sangamo Therapeutics Announces First Quarter 2025 Earnings Call\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-06T20:48:06+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250506737112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sangamo Therapeutics Announces First Quarter 2025 Earnings Call","datePublished":"2025-05-06T20:48:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\/"},"wordCount":336,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250506737112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\/","name":"Sangamo Therapeutics Announces First Quarter 2025 Earnings Call - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250506737112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-05-06T20:48:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250506737112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250506737112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sangamo-therapeutics-announces-first-quarter-2025-earnings-call\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sangamo Therapeutics Announces First Quarter 2025 Earnings Call"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/847732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=847732"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/847732\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=847732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=847732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=847732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}